Ulcerative Colitis Market Value Information,
by type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis,
Pancolitis or Universal Colitis, and Fulminant Colitis), by Medication
(5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics)
- Forecast to 2022
Market Research Future published a
Half-Cooked research report on “Global Ulcerative
Colitis Market Value Research Report - Forecast till 2022” – Market
Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.
The market
for ulcerative colitis is growing due to increasing demand for biologics for
treating bowel disorders such as ulcerative collates and is propelling the
overall market growth of global ulcerative market. Higher inclination for
symptomatic therapeutic and drugs over surgeries, increase in patient
assistance programs, better treatment and management of inflammatory bowel
diseases, the arrival of advanced drugs in the market owing to healthier
investments in R&D programs are some of the key trends governing the
market. Moreover, drug manufacturers are actively focusing on advanced products
having higher efficiency. The growing patient population is an additional
factor anticipated to influence the market growth between 2016 and 2022. Also
the increase in patient assistance programs is a major driver of the market.
The provision of these programs by vendors will upsurge the preference for
branded drugs because the out-of-pocket burdens would be less as the drugs are
obtained at lower costs.
Global Ulcerative Colitis Market Value - Regional Analysis
The market
of ulcerative colitis is much higher in the Americas region. In Americas, North
America commands the largest market share of global Ulcerative Colitis Market
Value and is expected to grow at the same pace. Asia Pacific shows sufficient
cases recoded for the disease due to lack of infrastructure and awareness and
is expected to be the fastest growing segment with the highest CAGR due to
continuous improvement in healthcare sector and increasing awareness among
people. According to the US Center for Disease Control, there is an ulcerative
colitis prevalence of 238 per 100,000 adults. The number of ulcerative colitis
patients is increasing in emerging economies as per the development in
technology, these developing or emerging economies are expected to account for
the larger market share in coming future.
Allergan, Inc., AbbVie Inc., Takeda
Pharmaceutical Company Limited, Bayer AG, UCB S.A., Perrigo Company plc, Pfizer
Inc., Johnson & Johnson Services, Inc., Ferring B.V., Janssen Biotech, and
Merck are some of the leading players at the cutting edge of the competition in
the market of ulcerative Colitis, globally.
Key developments
Companies
are continuously developing new products to capture the market globally. Thus
major players invest more in research and development activity, in order to
lead the global market. In this regards, market players undertake various
strategic approaches.
Johnson & Johnson Services Inc.
September,
2016: Acclarent Inc., a subsidiary of Johnson & Johnson, received FDA
approval for ACCLARENT AERA Eustachian Tube Balloon Dilation System. It is a
first FDA-approved device to treat Eustachian Tube Dysfunction effectively.
March, 2016:
Ethicon, a medical device company of the Johnson & Johnson, acquired
NeuWave Medical, Inc.
June, 2015:
Verb Surgical Company was created by the collaboration of Ethicon and Verily.
March, 2015:
Ethicon, a medical device company of the Johnson & Johnson, enter into a
collaboration with Google, Inc.
Pfizer Inc.
Pfizer Inc.
is a leading research based bio pharmaceutical organization. Pfizer apply
science and our worldwide assets to convey inventive treatments that develop
and essentially enhance lives. Pfizer makes medicines and vaccines that help
individuals when they are sick and keep them from becoming sick in any case,
and additionally a portion of some of the world’s best-known consumer
healthcare brands.
August,
2016: FDA approves Pfizer's TROXYCA ER extended-release capsules CII for pain
management. This drug is used for abuse-deterrent properties for the management
of pain and will help Pfizer to improve their goodwill and sales with this new
product
July 2016:
Bind Therapeutics entered into an asset purchase agreement with Pfizer Inc.
Bind Therapeutics Inc. entered into an asset purchase agreement with Pfizer,
Inc. On July 26, 2016, company amended the stalking horse agreement. The
acquisition is expected to close on or about August 1, 2016.
July 2016:
Pfizer and Western Oncolytics announce immuno-oncology research collaboration.
This collaboration has the aim to investigate novel oncolytic virus technology.
Under terms of agreement, Pfizer and Western Oncolytics will collaborate on
preclinical, clinical development of WO-12 through Phase I trials. Financial
terms of agreement are not disclosed
June 2016:
Pfizer completed the acquisition of Anacor Pharmaceuticals. This acquisition
has a motive for Pfizer, so that the company can accelerate their shared
commitment to help patients with inflammatory disease, an area of high unmet
medical need
Merck:
January,
2017: Merck Acquired BioControl to Strengthen Position in Food Safety Testing
August,
2012: Merck Acquired Cell Culture Media Specialist Biochrom AG
Allergan
November,
2017- Allergan plc company announced its data will be presented at the annual
American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana, U.S.
Allergan has a portfolio of leading brands and best-in-class products for the
central nervous system, eye care, medical aesthetics and dermatology,
gastroenterology, women's health, urology and anti-infective therapeutic
categories. The company is an industry leader in Open Science, a model of
research and development, which defines company's approach to identifying and
developing ideas and innovation for better patient care.
August,
2016- Allergan acquired eye care company ForSight VISION5 which added
peri-ocular ring technology to Company's leading portfolio of innovative eye
health products. Allergan has been a leader in the development and introduction
of novel treatments for underserved eye conditions, including glaucoma, chronic
dry eye disease and other ocular conditions. According to company reports, this
acquisition of this ring technology that has profoundly change the way patients
receive treatment. The ring is a preservative-free, non-invasive peri-ocular
product that rests on the surface of the eye .It is inserted by an
Ophthalmologist or Optometrist, and releases medication (bimatoprost) over
multiple months to lower elevated IOP in glaucoma and ocular hypertensive
patients.
No comments:
Post a Comment